Literature DB >> 2256808

Cardiac rehabilitation after coronary artery bypass grafting: effects on exercise performance and risk factors.

B E Hedbäck1, J Perk, J Engvall, N H Areskog.   

Abstract

After coronary artery bypass grafting (CABG), 49 nonselected patients followed a cardiac rehabilitation program that included medical follow-up and physical training, both in outpatient groups and on an individual basis at home. The effect of the program on exercise test variables, coronary risk factors, and medication one year after surgery was compared to a nonexercised control group (n = 98). The study group showed less increase in the rate-pressure product, indicating a favorable effect on myocardial oxygen consumption (0.7 +/- 5.4 vs 2.8 +/- 5.6, p less than .05); a lower frequency of angina at exercise testing (6% vs 18%, p less than .01); a reduction in resting systolic and diastolic blood pressure (9/4mmHg, p less than .01); fewer smokers (6% vs 17%, p less than .05); and fewer patients taking long-acting nitrates (0% vs 10.2%, p less than .05). It is suggested, therefore, that an organized cardiac rehabilitation program may be advantageous after CABG.

Entities:  

Mesh:

Year:  1990        PMID: 2256808

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  2 in total

Review 1.  Rehabilitation in cardiac patients:what do we know about training modalities?

Authors:  Dominique Hansen; Paul Dendale; Jan Berger; Romain Meeusen
Journal:  Sports Med       Date:  2005       Impact factor: 11.928

2.  Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263].

Authors:  Kate Jolly; Gregory Y H Lip; Josie Sandercock; Sheila M Greenfield; James P Raftery; Jonathan Mant; Rod Taylor; Deirdre Lane; Kaeng Wai Lee; A J Stevens
Journal:  BMC Cardiovasc Disord       Date:  2003-09-10       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.